vialroom

#cagrilintide 2026-05-16

Saturday47 messages9 participantstimes are UTC
Highlights from this day
  • provincial_pat — weekly for me, same day every week, no reason beyond habit 11:12
  • rezept_rolf — the reason nausea reads differently is timing, mine arrived on the second day rather than the first 11:42
  • provincial_pat — held at 2.5 for 3 months on monotherapy before i touched it again 12:07
  • rezept_rolf — while im here you cannot tell which of the two is doing what in a combination and i stopped pretending i could 13:08
  • lower_frequency — does the fullness effect fade the way appetite suppression does 13:10
AB

combination GI was worse than either alone for me, which is not what i had read anywhere

PP

CagriSema is cagrilintide with semaglutide and REDEFINE is the trial programme around it, i have it written down somewhere

if youre used to GLP-1 titration steps this feels absurdly cautious and i still do it that way

PP

i said earlier this year that monotherapy did nothing for me, and at a higher dose it did something

PP

two PeptideMeter results on the same HJ lot came back 99.4 and 96.8, closer than i expected
the slower titration in here is community habit as much as anything, the trials had their own schedule

weekly for me, same day every week, no reason beyond habit

Cited study
Efficacy and Safety of Cagrilintide in Adults with Overweight or Obesity — Phase 2
The Lancet · 2021
Cagrilintide monotherapy, dose ranging. The combination trials came later.

while im here monotherapy question, did appetite move for you without a GLP-1 alongside

i was sceptical about monotherapy and after 21 months im still sceptical, just less so

📉6❤️1
RR

the fullness thing is the part people describe differently, food stops being interesting rather than repellent

did the combination change your GI compared to the GLP-1 alone

held mine a while

RR

the reason nausea reads differently is timing, mine arrived on the second day rather than the first

👍10
PP

dropped the GLP-1 and stayed on this alone for 23 months, appetite held but weight barely moved

held at 2.5 for 3 months on monotherapy before i touched it again

👀4⚠️6🤝2

the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing

its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake

combination for me

unrelated but amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist

*Janoshik not the other one

BB

while im here dosing them on different days made no difference i could detect

CO

while im here nobody should copy my schedule, im describing it because people asked what a slow ramp looks like

RR

while im here you cannot tell which of the two is doing what in a combination and i stopped pretending i could

🙏12
LF

does the fullness effect fade the way appetite suppression does

🧪5💀17❤️15
BB

stopped for 19 months and the fullness went within a fortnight of the last dose
two Medutest results on the same KP lot came back 99 and 97.4, closer than i expected

how slow are people titrating this compared to semaglutide

added it to an existing cagrilintide dose rather than starting both, which made attribution possible, still working it out

went slower because the first step gave me two rough days and i took that as information

REDEFINE is the phase 3 programme, most of what gets quoted casually in here is earlier work

CO

changed my mind on this, i started thinking amylin was the interesting bit and now i think its the pairing, i have it written down somewhere

the slower titration in here is community habit as much as anything, the trials had their own schedule

📈1

amylin analogue, so its not a GLP-1 at all right

slower than the others

RR

the numbers everyone quotes come from the combination, so comparing them to monotherapy logs is unfair

VB

On this day 2 years ago this channel logged 61 messages.